Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by VICTOR PRIETO and MADELEINE DUVIC.
VICTOR PRIETO
Connection Strength
3.161
MADELEINE DUVIC
  1. CD4/CD8 double-negative mycosis fungoides with large cell transformation and involvement of the lungs and leptomeninges. Dermatol Online J. 2022 Mar 15; 28(2).
    View in: PubMed
    Score: 0.206
  2. Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall. J Dermatol. 2020 Oct; 47(10):e354-e355.
    View in: PubMed
    Score: 0.185
  3. Necrotizing Granulomatous Dermatitis and Panniculitis Masquerading as T Cell Lymphoma. Skinmed. 2019; 17(6):406-408.
    View in: PubMed
    Score: 0.175
  4. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017 Feb; 44(2):158-176.
    View in: PubMed
    Score: 0.144
  5. Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries. Cancer Med. 2015 Sep; 4(9):1440-7.
    View in: PubMed
    Score: 0.130
  6. Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries. Cancer. 2015 Jun 15; 121(12):1993-2003.
    View in: PubMed
    Score: 0.127
  7. Stenotrophomonas maltophilia with histopathological features mimicking cutaneous gamma/delta T-cell lymphoma. Int J Infect Dis. 2015 Jan; 30:7-9.
    View in: PubMed
    Score: 0.124
  8. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol. 2014 Mar; 53(3):376-84.
    View in: PubMed
    Score: 0.113
  9. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor. Am J Dermatopathol. 2013 Feb; 35(1):125-8.
    View in: PubMed
    Score: 0.110
  10. A case of invisible leukemic cutaneous T cell lymphoma with a regulatory T cell clone. Int J Dermatol. 2013 Sep; 52(9):1111-4.
    View in: PubMed
    Score: 0.102
  11. Clusterin expression correlates with stage and presence of large cells in mycosis fungoides. Am J Clin Pathol. 2009 Apr; 131(4):511-5.
    View in: PubMed
    Score: 0.084
  12. Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients. Clin Exp Dermatol. 2009 Jul; 34(5):576-81.
    View in: PubMed
    Score: 0.083
  13. Common variable immunodeficiency syndrome associated with epidermodysplasia verruciformis. Am J Clin Dermatol. 2007; 8(5):307-10.
    View in: PubMed
    Score: 0.072
  14. Multiple plaques on the hands and feet. Mycosis fungoides (MF) palmaris et plantaris (MFPP). Arch Dermatol. 2007 Jan; 143(1):109-14.
    View in: PubMed
    Score: 0.072
  15. Segmental neurofibromatosis in association with a large congenital nevus and malignant melanoma. Dermatol Online J. 2006 Dec 10; 12(7):22.
    View in: PubMed
    Score: 0.072
  16. High flotillin-2 expression is associated with lymph node metastasis and Breslow depth in melanoma. Melanoma Res. 2006 Oct; 16(5):461-3.
    View in: PubMed
    Score: 0.071
  17. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood. 2006 Jan 15; 107(2):463-6.
    View in: PubMed
    Score: 0.066
  18. Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res. 2004 Oct 15; 64(20):7361-9.
    View in: PubMed
    Score: 0.062
  19. Adult Langerhans cell histiocytosis limited to the skin. Dermatology. 2003; 207(2):157-61.
    View in: PubMed
    Score: 0.055
  20. Persistent atypical lymphocytic hyperplasia following tick bite in a child: report of a case and review of the literature. Pediatr Dermatol. 2001 Nov-Dec; 18(6):481-4.
    View in: PubMed
    Score: 0.050
  21. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders? Virchows Arch. 2021 Aug; 479(2):377-383.
    View in: PubMed
    Score: 0.048
  22. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features. J Cutan Pathol. 2019 Nov; 46(11):872-877.
    View in: PubMed
    Score: 0.043
  23. Differential expression of CCR4 in primary cutaneous gamma/delta (?/d) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy. J Dermatol Sci. 2018 Jan; 89(1):88-91.
    View in: PubMed
    Score: 0.038
  24. Immunophenotypic Shifts in Primary Cutaneous ?d T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens. Am J Surg Pathol. 2017 Apr; 41(4):431-445.
    View in: PubMed
    Score: 0.037
  25. Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators. Oncoimmunology. 2017; 6(5):e1306618.
    View in: PubMed
    Score: 0.036
  26. Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (?d) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous ?d T-Cell Lymphomas. Am J Surg Pathol. 2017 Feb; 41(2):204-215.
    View in: PubMed
    Score: 0.036
  27. Primary Cutaneous Gamma-Delta (?/d) T-cell Lymphoma: An Unusual Case With Very Subtle Histopathological Findings. Am J Dermatopathol. 2016 10; 38(10):e147-9.
    View in: PubMed
    Score: 0.035
  28. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol. 2016 Dec; 43(12):1161-1166.
    View in: PubMed
    Score: 0.035
  29. 4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. Melanoma Res. 2016 Apr; 26(2):181-7.
    View in: PubMed
    Score: 0.034
  30. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. Hum Pathol. 2016 Apr; 50:79-89.
    View in: PubMed
    Score: 0.033
  31. Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. Hum Pathol. 2015 Apr; 46(4):558-69.
    View in: PubMed
    Score: 0.031
  32. Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy. Am J Dermatopathol. 2014 Jul; 36(7):557-61.
    View in: PubMed
    Score: 0.030
  33. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. J Cutan Pathol. 2014 Mar; 41(3):326-8.
    View in: PubMed
    Score: 0.029
  34. Immunophenotypic shift of CD4 and CD8 antigen expression in primary cutaneous T-cell lymphomas: a clinicopathologic study of three cases. J Cutan Pathol. 2014 Jan; 41(1):51-7.
    View in: PubMed
    Score: 0.029
  35. BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. Elife. 2013 Nov 05; 2:e00969.
    View in: PubMed
    Score: 0.029
  36. The differential diagnosis of CD8-positive ("type D") lymphomatoid papulosis. J Cutan Pathol. 2014 Feb; 41(2):88-100.
    View in: PubMed
    Score: 0.029
  37. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist. 2013; 18(3):314-22.
    View in: PubMed
    Score: 0.028
  38. Bi-clonal, multifocal primary cutaneous marginal zone B-cell lymphoma: report of a case and review of the literature. J Cutan Pathol. 2012 Sep; 39(9):866-71.
    View in: PubMed
    Score: 0.026
  39. Annular plaques: An unusual manifestation of graft-versus-host disease. Dermatol Online J. 2012 Jun 15; 18(6):4.
    View in: PubMed
    Score: 0.026
  40. In vivo diagnosis of melanoma and nonmelanoma skin cancer using oblique incidence diffuse reflectance spectrometry. Cancer Res. 2012 Jun 01; 72(11):2738-45.
    View in: PubMed
    Score: 0.026
  41. Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. Melanoma Res. 2012 Apr; 22(2):169-75.
    View in: PubMed
    Score: 0.026
  42. Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/S?zary syndrome. J Cutan Pathol. 2011 Mar; 38(3):295-7.
    View in: PubMed
    Score: 0.024
  43. In-vivo characterization of optical properties of pigmented skin lesions including melanoma using oblique incidence diffuse reflectance spectrometry. J Biomed Opt. 2011 Feb; 16(2):020501.
    View in: PubMed
    Score: 0.024
  44. Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur J Cancer. 2011 Jan; 47(1):107-15.
    View in: PubMed
    Score: 0.023
  45. Transillumination as a means to differentiate melanocytic lesions based on their vascularity. Arch Dermatol. 2009 Sep; 145(9):1060-2.
    View in: PubMed
    Score: 0.022
  46. Atypical histologic and immunohistochemical findings in melanocytic nevi after liquid nitrogen cryotherapy. J Am Acad Dermatol. 2009 Aug; 61(2):341-5.
    View in: PubMed
    Score: 0.021
  47. Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat. 2008 Dec; 29(12):1443-51.
    View in: PubMed
    Score: 0.021
  48. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer. 2008 May 01; 122(9):2077-84.
    View in: PubMed
    Score: 0.020
  49. Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J Invest Dermatol. 2008 Jun; 128(6):1585-8.
    View in: PubMed
    Score: 0.019
  50. Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. Clin Cancer Res. 2007 Nov 01; 13(21):6532-9.
    View in: PubMed
    Score: 0.019
  51. Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. Cancer. 2007 Apr 15; 109(8):1570-8.
    View in: PubMed
    Score: 0.018
  52. Oral-cutaneous CD4-positive T-cell lymphoma: a study of two patients. Am J Dermatopathol. 2007 Feb; 29(1):62-7.
    View in: PubMed
    Score: 0.018
  53. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2006 Dec; 15(12):2526-32.
    View in: PubMed
    Score: 0.018
  54. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol. 2007 Feb; 127(2):276-80.
    View in: PubMed
    Score: 0.018
  55. Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis. 2006 Sep; 27(9):1894-901.
    View in: PubMed
    Score: 0.017
  56. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics. 2006 Apr; 16(4):253-63.
    View in: PubMed
    Score: 0.017
  57. In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. J Natl Cancer Inst. 2005 Dec 21; 97(24):1822-31.
    View in: PubMed
    Score: 0.017
  58. Primary S?zary syndrome commonly shows low-grade cytologic atypia and an absence of epidermotropism. Am J Clin Pathol. 2005 Apr; 123(4):510-5.
    View in: PubMed
    Score: 0.016
  59. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005 Feb 01; 23(4):759-65.
    View in: PubMed
    Score: 0.016
  60. Skin cancer detection by spectroscopic oblique-incidence reflectometry: classification and physiological origins. Appl Opt. 2004 May 01; 43(13):2643-50.
    View in: PubMed
    Score: 0.015
  61. Mycosis fungoides-like reaction in a patient treated with Gleevec. J Cutan Pathol. 2003 Apr; 30(4):279-81.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.